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The urinary steroidal fraction has been extensively explored as non-invasive alternative to monitor
pathological conditions as well as to unveil the illicit intake of pseudo-endogenous anabolic steroids in
sport. However, the majority of previous approaches involved the a priori selection of potentially relevant
target analytes. Here we describe the non-targeted analysis of the urinary steroidal profiles. The work-
flow includes minimal sample pretreatment and normalization according to the specific gravity of urine,
a 20 min reverse phase ultra-performance liquid chromatographic separation hyphenated to electro-
spray time-of-flight mass spectrometry. As initial validation, we analyzed a set of quality control urines
spiked with glucurono- and sulfo-conjugated steroids at physiological ranges. We then applied the
method for the analysis of samples collected after single transdermal administration of testosterone in
hypogonadal men. The method allowed profiling of approximately three thousand metabolic features,
including steroids of clinical and forensic relevance. It successfully identified metabolic pathways mostly
responsible for groups clustering even in the context of high inter-individual variability and allowed the
detection of currently unknown metabolic features correlating with testosterone administration. These
outcomes set the stage for future studies aimed at implementing currently monitored urinary steroidal
markers both in clinical and forensic analysis.
© 2017 Elsevier B.V. All rights reserved.3 Zurich, Switzerland1. Introduction
In the last decades the urinary steroidal profile has caught
increasing interest as an alternative, non-invasive way to monitor
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related therapies [1e8]. Its diagnostic value has been explored in
adrenal tumors as well as prostate cancer, hypogonadism, and
other secondary sexual dysfunctions [9e12]. In anti-doping tests, it
has been considered for the detection of systemic intake of corti-
sone and hydrocortisone [13] and currently provides the reference
landscape to unveil the use of endogenous anabolic steroids
[14e16]. In this regard, testosterone and its precursors are one of
themost abused classes of doping substances in sport. Although the
unambiguous, direct confirmation of the exogenous origin of these
steroids is obtained by gas chromatography coupled to isotopic
ratio mass spectrometry (GC-IRMS) [17e19], this technique is still
relatively complex and costly, and it is not yet performed on all
urine samples received by the anti-doping laboratories. Conse-
quently, the initial testing procedure relies on the detection and
quantification of targeted steroids in urine. More precisely, since
2014 the World Anti-Doping Agency has approved the so called
“Steroidal Module” of the Athlete Biological Passport (ABP), meant
as a record over time for each athlete of the urinary concentrations
of six steroidal markers (Testosterone (T), Epitestosterone (E),
Androsterone (Andro), Etiocholanolone (Etio), 5a-androstane-
3a,17b-diol (5aAdiol) and 5b-androstane-3a,17b-diol (5bAdiol)) as
sum of free and glucuronides (G), together with their relative ratios
and the specific gravity of the sample [20e22]. Obtained data are
integrated in a Bayesian adaptive model that allows for the pro-
gressive replacement of previously applied population-based
thresholds with personalized reference ranges [23]. The recent
introduction of this strategy in routine analysis led to a significant
improvement of the efficacy of the initial testing procedure for
pseudo-endogenous anabolic androgenic steroids. Indeed, high
level of specificity and robustness has been demonstrated in the
case of oral or parenteral intake of T and related steroids [24e27].
However, its limits, for instance in the recognition of topical ap-
plications and in the context of long-term regimes, have been
recently highlighted and still constitute an open question [28e32].
These aspects raised the need of developing alternative meth-
odologies allowing the comprehensive exploration of the urinary
steroidal fraction in the perspective of an evolution of the steroidal
module towards a more resolved overview of metabolic modifica-
tions indicative of the doping offence. In this regard, according to
classical targeted approaches, the general strategy followed for the
development and implementation of analytical methods aimed at
unraveling the intake of exogenous compounds includes the eval-
uation of the metabolic stability and of the excretion profile of the
substance in order to select the most appropriate analytical
marker(s) [33] (Fig. 1). This task is usually achieved performing
in vitro and/or in vivo metabolism studies in combination with gas
or liquid chromatography - mass spectrometry detection. The for-
mation of specific metabolites is hypothesized on the basis of the
current available knowledge and confirmed by the interpretation of
data obtained by targeted analysis. Unfortunately, a priori as-
sumptions often lead to results strongly biased by the absence of a
complete understanding of the metabolic scenario in the biological
system under investigation. In addition, even if not always pre-
dictable during the study design phase, significant quantitative and
qualitative differences of the excretion profile have been observed
depending on the particular route of administration of the sub-
stance, reflecting diverse sequences of metabolic reactions and
enzymes distribution [30,34e36].
In an effort to encompass these matters and to increase the
metabolic coverage of available methodologies, system-level ap-
proaches have recently found a variety of applications in bio-
markers discovery. In particular, early studies in this direction have
already unearthed previously unsuspected metabolic connections
also in the anti-doping field. This is for example the case reported ina recent work by Wang et al. describing the association between
salbutamol administration and purine metabolism [37]. Kiss et al.
applied a non-targeted strategy to explore metabolic differences in
urines collected by a group of volunteers and sportsmen and the
changes induced by the administration of salbutamol or budeso-
nide, remarking the utility of global approaches in the study of large
cohorts of samples presenting high inter-individual variability [38].
Concerning endogenous anabolic androgenic steroids, the use of T
formulations by oral route has been tackled by Boccard et al.
pointing out the importance of detecting both glucuronated and
sulfated (S) steroidal conjugates in urine [39], and suggesting a set
of biomarker candidates [40]. In a further investigation, Raro et al.
revealed the increase in 1-cyclopentenoylglycine excretion in urine
after intramuscular injection of T cypiotane [41]. These findings
have extended the currently available information in support of a
scrupulous examination of data acquired in routine analysis,
endorsing the utility of comprehensive, fast and reliable analytical
workflows for the broad exploration of the metabolic content of
samples in a non-targeted fashion [42].
Here we present a comparative metabolomics strategy based on
ultra-performance liquid chromatography e time of flight mass
spectrometry with electrospray ionization (UHPLC-ESI-qTOF MS)
and data processing in the open source OpenMS [43] environment
for the non-targeted exploration of the urinary metabolic profile,
ensuring the detection of steroids of relevance in clinical and anti-
doping research directly in the form of G and S conjugate metab-
olites (Fig. 2). In order to validate the approach, groups of urine
samples spiked with endogenous steroid metabolites at concen-
trations within human physiological ranges were analyzed. We
eventually applied the non-targeted strategy to explore the meta-
bolic signature of samples collected before and after single trans-
dermal administration of testosterone gel in a population of
hypogonadal non-hospitalized patients.
2. Materials and methods
2.1. Chemicals and reagents
Solvents and chemicals were of analytical or HPLC grade and
provided by Sigma-Aldrich (Schnelldorf, Switzerland). Water was
obtained from a MilliQ water purification system (Millipore S.p.A.,
Milano, Italy). API-TOF reference mass solution kit containing pu-
rine, ammonium trifluoroacetate (ammonium TFA) and
hexakis(1H,1H,3H-tetrafluoropropoxy) phosphazine (HP-0921)
was from Sigma-Aldrich (Schnelldorf, Switzerland). Internal
deuterated standards (d4-androsterone glucuronic acid (AndroG-
d4), d4-androsterone sulfate (AndroS-d4) triethylammonium salt,
d4-5a-androstan-3a,17b-diol-17b-glucuronic acid (5aAdiolG-d4),
d3-5b-androstan-3a,17b-diol-17b-glucuronic acid (5bAdiolG-d3))
and other steroidal standards (epitestosterone glucuronic acid (EG),
testosterone glucuronic acid (TG), etiocholanolone glucuronic acid
(EtioG) sodium salt, androsterone sulfate (AndroS) triethylammo-
nium salt, dehydroisoandrosterone sulfate (DHEAS) sodium salt
dehydrate) were from LGC Standards (Milano, Italy). Stock standard
solutions were prepared in methanol at the concentration of 1 mg/
mL and 0.01 mg/mL (referred to the salt) and stored at 20 C until
use.
2.2. Sample preparation
Urine samples were thawed at room temperature and subject to
a minimal sample preparation protocol including volume normal-
ization according to the specific gravity (SG) of the sampleBriefly,
SG was measured by refractometry and variable aliquots of sam-
ples, calculated with the formula 100 mL * 1.02/SG, were transferred
Fig. 1. Workflow for the development/implementation of analytical methods aimed at unraveling the intake of exogenous compounds. The metabolic stability of the substance is
assessed either in vitro or in vivo performing classical targeted hypothesis testing studies or with more comprehensive non-targeted approaches.
Fig. 2. Representation of the non-targeted pipeline. Urines undergo volume normalization according to the specific gravity of the sample, evaporation, reconstitution in the mobile
phase and direct injection in the LC-MS system. Mass spectra acquisition is performed in full scan mode, followed by spectra preprocessing in a semi-automated pipeline based on
OpenMS algorithms implemented in the KNIME Analytical Platform environment including mass spectra internal calibration, baseline correction, feature detection by means of
FeatureFinderMetabo, retention time correction and features alignment. The obtained dataset is preliminary annotated against the Human Metabolome Data Base gathering a
report including retention time, experimental m/z, calculated m/z, mass error, annotation, database ID, chemical formula, ion abundance, neutral mass, adducts description and
smile structures for each detected feature. Data can be visualized in the KNIME environment or exported in.csv format for further pretreatment. A combination of uni- and multi-
variate statistical approaches is used for data dimensionality reduction. Identity of a subset of selected features is eventually confirmed analyzing MS/MS fragments, retention time,
isotopic pattern and standards.
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taining four deuterated standards (AndroG-d4, AndroS-d4,
5aAdiolG-d4, 5bAdiolG-d3 for final concentration of 2000 ng/mL,
2000 ng/mL, 100 ng/mL and 100 ng/mL, respectively) were added
and samples evaporated to dryness under vacuum at room tem-
perature. For spiked quality control samples, additional 10 mL of a
methanolic solution containing EG, TG, EtioG, AndroS and DHEAS
(for final concentrations of 100, 100, 2000, 2000, and 2000 ng/mL,
respectively) were added.
After evaporation, all samples were reconstituted in 100 mL of
acetonitrile/weather (10/90 v/v), vortexed, centrifuged at
10.000 g at 4 C for 5 min, the supernatant transferred in a 96-well
plate and injected in the UHPLC-qTOF system. In order to increase
the sensitivity for steroidal metabolites in physiological concen-
tration ranges, different sample dilutions were evaluated (including
10, 5, 2 fold), undiluted and 5, 10-fold concentration as well as
different compositions of the reconstitution solution.
2.3. Chromatographic and mass spectrometric conditions
Chromatographic separationwas performed using an ultra-high
pressure chromatographic system (UHPLC) equipped with an
Acquity UHPLC BEH C18 (2.1  5 mm, 1.7 1.7 mm) Van Guard pre-
column in combination with an Acquity UHPLC BEH C18 column
(2.1 150mm,1.7 mm). Asmobile phases 0.01% formic acid inwater
(A) and 0.01% formic acid in acetonitrile (B) were used. After
evaluation of different elution gradients and column temperatures,
the final conditions were as follow: 15% B from 0 to 1 min, 40% B
from 1 to 8.2 min, 40% B until 9.8 min, 95% B from 9.8 to 13.5 min,
95% B until 14.5 min, 15% B from 14.5 until the end of the run. The
total chromatographic run time was 16.5 min, column temperature
30 C and flow rate at 0.3 mL/min. Samples were maintained at 8 C
until injection of 10 mL in the UHPLC/MS system.
Liquid chromatographic mass spectrometric profiles were ac-
quired on an Agilent 6520 Quadrupole Time of Flight (Agilent
Technologies) with an electrospray ion source operated in dual ESI
negativemode. Gas temperaturewas set at 365 C, drying gas at 6 l/
min and nebulizer pressure at 30 psig. The capillary voltage was at
3500 V, fragmentor at 200 V and skimmer at 65 V. Mass acquisition
was performed at 1 spectra/s for a total transients/spectrum of
9902. For continuous on line recalibration ofm/z axes TFA anion (m/
z 112.985587) and HP-0921 (m/z 1033.988109) were infused in the
MS systemwith lock spry nebulizer pressure set at 10 psig. Full scan
centroided mass spectra were acquired in 4 GHz high resolution
mode in the range 50e1050 m/z. For tandem MS fragmentation
studies, the quadrupole was set to allow the selection of targeted
[M  H] ions in narrow (1.3 m/z) isolation width mode. Precursor
ions were fragmented at fixed collision energies (10, 20 and 40 eV).
2.4. Observational study and quality control samples
Samples were collected in the framework of an observational
study involving 19 male non-hospitalized patients diagnosed with
hypogonadism and other related secondary sexual disorders (one
of them, 25 years old, was diagnosed with retarded puberty). Each
subject gave informed consent in writing. All patients were be-
tween 25 and 79 years old and none of them has undergone other
hormonal replacement therapies in the 35 days before the obser-
vational study. T was administered in the form of Tostrex Gel 2%®
(ProStrakan Ltd, Tredegar, UK) containing 20 mg T per gram of gel.
Urine samples were self-collected by each patient immediately
before, 2e3, and 24 h after the administration using sterile Falcon
tubes. Each subject took 4 puff of Tostrex Gel for an approximate
single total dose of 40 mg T (bioavailability ranging from 7 to 10%).
In order to comply with the physiological circadian rhythm ofpatients, the drug was administered in the morning. In addition, to
have a complete overview on each subject, all information
regarding age, comorbidity, basal temperature and previous sub-
stitutive hormonal therapies were collected. Additional urine
samples were obtained by two healthy volunteers (aged 24 and 27
years) and used for the preparation of blank and spiked quality
controls. All samples were stored at e 20 C until analysis.
2.5. Batch analysis
The analytical batch was composed of study samples inter-
spersed by two different sets of quality controls as to cover at least
10% of the entire sequence (for a total of twelve injections for each
set). Quality Controls 1 (QC1) consisted of samples obtained by
healthy male volunteers (between 24 and 27 years) prepared ac-
cording to the minimal sample preparation procedure previously
described. The same samples were spiked with anabolic steroids
metabolites within male physiological urinary range and analyzed
as Quality Controls 2 (QC2). Before analysis, a set of ten QC1 was
injected to condition and equilibrate the system. Quality control
data were processed and analyzed in order to evaluate retention
time drift and mass spectrometric variability. All samples were
analyzed in duplicate.
2.6. Data processing and statistical analysis, metabolite
identification
Raw data were pre-processed on large scale in a semi-
automated pipeline developed in the KNIME Analytics Platform
(Konstanz, Germany) [44] implemented with openMS nodes [43]
(see Figure S-1 for a detailed schematization of the data process-
ing and analysis workflow). Input data were internally recalibrated
and LC-MS features detected with FeatureFinderMetabo [45]. The
following conditions, deducted from the analysis of quality controls
spectra in Mass Hunter Qualitative Analysis B07 (Agilent Technol-
ogies, San Jose, CA, USA) (see below), were used for features
detection: noise intensity threshold 1500 counts, mass error
10 ppm with dynamic re-estimation of m/z variance during mass
trace collection, isotope model set as “general metabolites” and
isotope noise model with 5% RMS error. The integration was iter-
atively repeated for all samples in a loop-architected workflow.
Retention time was corrected considering 0.15 min of variability.
Detected features were then merged in a consensus map for
retention time alignment and filtered in the range 2e14.2 min and
300e850 m/z. Preliminary putative annotation against the Human
Metabolome Database (www.hmdb.ca) was performed at 10 ppm
mass error considering the [M - H] and other major expected ad-
ducts ([M - H], [M þ CH2O2-H], [M þ Na-2H], [MþCl], [M - 2H],
[M - 3H], [M þ K-2H], [2M - H], [2 M þ CH2O2-H]). The resulting
dataset was exported for further pre-treatment in Matlab. Briefly,
features with more than a defined threshold for missing values
(normally set at 80%) were removed and the remaining ones
replaced by a value equal to the noise threshold (1500 counts).
Samples were normalized for the total signal, log transformed,
mean centered and divided by the standard deviation of each var-
iable (z-scored). The final dataset was explored with uni- and
multi-variate analysis in R and Matlab. For multiple t-test we
considered the q-values which give a more accurate indication of
the level of false positives when testing dataset with high number
of features [46]. The significance cut-off was set at 0.05. In addition,
the dataset was explored with Principal Component Analysis (PCA)
and Partial Least Squares Discriminant Analysis (PLS-DA). Features
with Variable Important in Projection (VIP) values> 1 in the PLS-DA
model and q-value < 0.05 were isolated. Among these, we
considered only those exhibiting increase. This subset was further
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both HMDB and scientific literature, retention time, isotopic
pattern and MS/MS fragmentation. Feature identity was confirmed
by comparison with data obtained for appropriate standards, when
available in our lab. MS/MS spectra were analyzed using Mass-
Hunter Qualitative Analysis B07.
3. Results and discussion
3.1. Sample pre-treatment and UHPLC-MS method optimization for
non-targeted analysis
We initially aimed at obtaining a non-targeted method ensuring
the detection of steroidal urinary metabolites of doping and clinical
relevance in the context of the global metabolic repertoire of the
sample. First injections were performed with 10-fold sample dilu-
tion in acetonitrile/water 10/90 v/v. Under these conditions we
detected a limited number of features and, among steroidal me-
tabolites of interest, only Andro and Etio glucuronides and sulfates
were evident (present in urine at high physiological concentrations,
> 2000 ng/mL [47]). In an effort to optimize sample preparation, in
order to increase the range of steroids covered by the method, we
characterized the chromatographic and dynamic response and
signal-to-noise ratio value for selected steroidal metabolites
included both in the ABP and among those of diagnostic relevance
in the interpretation of the steroidal profile in clinical practice.
Figure S-2 shows the extracted ion chromatograms for selected
standards; Table S-1 reports their relative order of elution andmass
to charge values for [M - H] ions. Different concentrations of
standards (5e2000 ng/mL, referred to the unconjugated steroid)
spiked in 100 mL acetonitrile/water 10/90 v/v were injected. For TG,
we found linear response (R2 > 0.99) in the entire investigated
range (5e2000 ng/mL) and signal to noise ratio higher than 3,
starting from 5 ng/mL. Identical results were obtained for EG, EtioG,
AndroG-d4, 5bAdiolG-d3, AndroS, AndroS-d4, DHEAS (Figure S-3).
Comparing these evidences with physiological urinary ranges re-
ported for a population of healthy Caucasian men [47], 5-fold
sample dilution, undiluted and 5-, 10-fold concentration were
tested. From the analysis of obtained mass spectra and taking into
account the future application of the method also for the analysis of
urine collected from hypogonadal subjects, we finally opted for a
minimal sample preparation with normalization of the volume of
undiluted samples according to specific gravity before evaporation
and reconstitution in 100 mL acetonitrile/water 10/90 v/v.
Steroids currently included in the ABP can be grouped in three
isomeric couples: T/E, Andro/Etio, 5aAdiol/5bAdiol (as sum of free
steroids and their G conjugated form, normally representing > 90%
of the total excretion). In order to limit the co-elution of these
analytes and other isobars, different chromatographic gradients
and column temperatures were tested, starting fromwhat reported
in previous work [40,41,48]. In the final method, the columnwas set
at 30 C and the elution was performed in gradient, starting from a
mobile phase composition (acetonitrile/water 15/85 v/v) similar to
the sample reconstitution solution (acetonitrile/water 10/90 v/v),
and gradually increasing the % of organic phase until 95% in 14 min,
followed by rapid re-equilibration for a total run time of 16.5 min.
Representative total ion chromatogram and chromatographic sep-
aration for AndroG/EtioG and related S forms obtained under these
settings are reported in Figures S-4, S-5.
Mass spectrometric conditions (nozzle, fragmentor, skimmer
voltage) were optimized for ESI () ionization of conjugated ste-
roids. In particular, visual analysis of mass spectra obtained for
single steroidal standards revealed the formation of dimeric steroid
ions [2M - H] (Figure S-6). In order to reduce these signals in favor
of the [M - H] molecular ion, the fragmentor voltage was varied,finding a good compromise at 200 V. The chromatographic and
mass spectrometric conditions described herein allowed to maxi-
mize the number of informative detected features in a total chro-
matographic run time of 16.5 min, minimizing sample
pretreatment and noise deriving from matrix interferences.
3.2. Data pretreatment optimization and quality control analysis
The reliability of LC-MS based metabolomics can be jeopardized
by retention time drift and variations in mass accuracy during the
sequence. These effects become particularly relevant when dealing
with the analysis of large size batches and can cause errors in data
pre-processing, features merging and annotation. In order to cope
with this issue, retention time relative standard deviation (RSD)
and mass to charge RSD for steroidal internal standards in quality
control urine samples (QC), injected after equilibration of the sys-
tem and approximately after every 10 study samples (for a total of
12 QC replicates), were evaluated (Table S-2, Figure S-7). Based on
these evidences, raw data were pre-processed considering 10 ppm
mass error for peak piking, isotope merging and annotation, and
0.15 min retention time tolerance for peak alignment. Of note, the
method also allowed to discriminate between the Andro G (or Etio
G) [M - H] ion and the [M-Hþ2] isotopologue of 5aAdiol G (or
5bAdiol G), which elute at different retention times. After pre-
processing mass spectra for QC samples collected from two vol-
unteers (analyzed as multiple technical replicates) using these
settings we detected approximately 800 individual features. These
entries were putatively annotated against the Human Metabolome
Database considering generally reported adducts for ESI () ioni-
zation mode. With these settings, >60% of detected features
received a preliminary putative annotation. Data underwent
further dimensionality reduction by eliminating all features with
>80% missing values, obtaining a dataset composed of approxi-
mately 320 entries. Furthermore, to obtain an estimation of the
reliability in measured abundances, we considered a set of twelve
replicates for the same urine sample. Coefficient of variation % (CV
%) (repeatability, n ¼ 12) was in the range ± 30% for > 75 features,
with median value at ± 10% (Figure S-8). Among these compounds,
the steroidal G and S conjugates reported in Table S-3 were puta-
tively annotated. Of note, we often obtained identical putative
annotation for features at different retention times. We therefore
attributed these features to steroidal isomeric forms and other
isobars not currently described in the humanmetabolome database
(as, for example, in the case of the four isomeric forms of cortolone
G) and trusted putative annotations only to reach a preliminary
overview on the metabolic coverage of the method. Moreover, we
also detected features with putative annotation corresponding to
the steroidal metabolites recently proposed as additional urinary
markers of testosterone intake (e.g., 6b-OH-androsterone-3-
glucuronide (6b-OHAndro G) and 6b-OH-etiocholanolone-3-
glucuronide (6b-OHEtio G) [49]).
As proof of concept, we applied the pipeline for the comparative
analysis of a blank quality control group (QC1) and a second group
obtained spiking the same urine with endogenous steroids within
urinary physiological concentration ranges previously reported for
themale Caucasian population (QC2) (Table 1) [47]. The data matrix
obtained by processing with OpenMS was pretreated as above
described (missing values replaced by the noise threshold (1500
counts), normalized for total signal, log transformed and z-scored)
and explored with principal component analysis (PCA). PCA
allowed a preliminary exploration of the dataset highlighting out-
liers (excluded from further analysis) and straightforward QC1 and
QC2 spontaneous groups clustering (Fig. 3A). In order to stress out
the separation between observed groups and rank features most
responsible for clustering, data were further investigated in a
Table 1
VIP scores obtained for steroids spiked in quality control samples, referred to the
first component of the PLS-DA model.
Compound Spiked concentration (ng/
mL)
VIP
score
Dehydroisoepiandrosterone
glucuronide
2000 2.6
Androsterone sulfate 2000 >3
Etiocholanolone glucuronide 2000 >5
Testosterone glucuronide 100 >3
Epitestosterone glucuronide 100 1.6
A. Palermo et al. / Analytica Chimica Acta 964 (2017) 112e122 117Partial Least Squares e Discriminant Analysis model (PLS-DA). In
contrast to PCA, PLS-DA maximizes the variance existent in the
dataset using the a priori knowledge of class assignments. Obtained
scores plot for PLS-DA first three components computed for QC1
and QC2 data is reported in Fig. 3B. Component one explained
approximately 18% of the entire variability, whereas component
two and three were less explicative. Therefore, we considered the
ranking list for variables important in projection (VIP) related to
component 1. These values account for the amount of explained
variation in each dimension in regard to single entries of the
dataset. As showed in Table 1, VIP values for all steroids spiked in
the QC2 group exhibit scores >1. Concerning other features
significantly increased in the QC2 group and with VIP >1, we found
some adducts of the spiked steroids corresponding to the sodium
formate cluster ([M þ HCOONa-H]). These adducts were confirmed
analyzing MS spectra obtained for pure standards (Figure S-11).
Eventually, when applied for the analysis of quality control
samples obtained by single spot urine collection from twoFig. 3. PCA and PLS-DA score plots based on quality controls data (A, B) and on samples an
(control group) and after (treatment group) single testosterone gel administration (C, D).volunteers, the here described method allows the detection of
approximately 800 features and a preliminary putative annotation
of >60% of them against the Human Metabolome Database,
considering 10 ppm error and main ESI () reported adducts.
Among these features, steroids of clinical and doping relevance are
detectable with high reliability on measured ion abundance, mak-
ing the method appropriate also for relative metabolite quantifi-
cation. In addition, PLS-DA analysis and VIP ranking revealed the
influence in group clustering of steroids spiked in the QC2 group
and the suitability of this approach for the comparative investiga-
tion of the urinary steroidal profile of Caucasian men in the context
of the urinary metabolic repertoire.3.3. Comparative analysis of urines after single transdermal
testosterone administration
To explore the applicability of the non-targeted workflow, we
investigated the metabolic signature of urines collected in the
framework of an observational study involving 19 males in treat-
ment with transdermal T. Topical formulations of T are generally
indicated in the therapy of common pathological conditions
including male hypogonadism and other secondary sexual disor-
ders. In general, these pharmaceutical preparations are considered
a gold standard in all those cases in which local action and limited
systemic adsorption are advisable. Due to the low relative
bioavailability, modest modifications of the urinary steroidal profile
are normally expected after treatment. This study involved non-
hospitalized patients between 25 and 79 years old (median age
62), diagnosed with Latent Onset Hypogonadism syndrome (LOH)
and related secondary sexual disorders. Testosterone was self-alyzed in the framework of the observational study involving hypogonadal men prior
A. Palermo et al. / Analytica Chimica Acta 964 (2017) 112e122118administered topically, between 09:00 and 10:00 in the morning,
for a single total dose of 40 mg (bioavailability from 7 to 10%). Urine
collection started immediately before the application (control),
followed by sampling at approximately 2e3 h (treatment) and 24 h
(elimination) after the intake. Samples were divided in three
groups according to the expected excretion profile. MS analysis and
processing of the urine samples lead to the identification of >3000
metabolic features, of which >60% putatively annotated.
Considering the intrinsic high inter-individual variability of the
population under investigation due to relevant difference in age
and the presence of diverse comorbidities (including, but not
limited to, diabetes, hypertension, leukemia, depression), and in
view of the possible detection of metabolites only after treatment,
the dataset was reduced by eliminating features with >90%missing
values. The resulting 1100 features were normalized and scaled.
The coefficient of variation % for technical replicates was found
included in the range ±30% for approximately 300 features in each
sample, with median value < 10% (Figure S-9). Preliminary explo-
ration of the obtained multidimensional dataset with PCA failed in
underline any clustering and confirmed the expected broad meta-
bolic inter-individual variability (Fig. 3C). In such confused data,
supervised multivariate methods can provide valuable help inTable 2
Proposed annotation for selected steroids. VIP, variable importance in projection, Rt, reten
only putatively annotated.
VIP score Measured [M - H] m/z Calculated [M - H] m/z Error (ppm)
2.83 367.1009 367.1035 6.8
1.79 367.1005 367.1035 8.1
1.82 439.1591
1.87 541.2613 541.2654 7.6
1.49 541.2656 541.2654 0.4
2.17 445.2001 445.1994 1.6
1.52 541.2623 541.2654 5.7
1.82 541.2650 541.2654 0.7
1.39 539.2510 539.2497 2.4
1.68 509.2662
1.65 479.2192 479.2286 7.3
1.29 481.2436 481.2443 1.5
2.4 511.2501
1.83 479.2251 479.2287 7.5
1.58 463.2280 463.2337 5.6
1.97 463.2293 463.2337 9.5isolating only the informative fraction from high-dimensional
datasets. In this regard, PLS-DA modeling and VIP scores analysis
returned the expected group clustering (Fig. 3D). All features
exhibiting VIP >1 (referred to the first score component, explaining
approximately 10% of the total variance) were isolated. This subset
was further filtered i) retaining only features increased after
treatment and ii) responding to a significance threshold set at 0.05
for p-values corrected for multiple testing (q-values). Each feature
in agreement with these criteriawas confirmed by visual analysis of
mass spectra and evaluation of the short-term excretion profile
considering control, treatment and elimination groups. This pro-
cedure led to the list of metabolites reported in Table 2.
Putative annotation of these compounds was confirmed in MS/
MS experiments underlining the loss of the glucuronic group and
the formation of fragments previously reported for steroidal con-
jugates [50,51] or present in in silico predicted spectra [52] (see
Table S-4). For TG and EG, both fragmentation and retention times
were also consistent with data obtained analyzing pure standards
(Figure S-11). The possibility of the detection of two isotopic forms
deriving from the same metabolite for features co-eluting at
7.5 min (m/z of 541.265 and 539.250) was excluded by the analysis
of the isotopic pattern (Figure S-10). Beyond putative annotationstion time, HMDB ID, Human Metabolome Database identification code. *metabolites
Rt (min) Annotation HMDB ID
3.8 M1 Caffeoyl methylquinic acid* HMDB39960
Ferulylquinic acid* HMDB30669
4.0 M2 Caffeoyl methylquinic acid* HMDB39960
Ferulylquinic acid* HMDB30669
6.8 M3 e e
6.8 20a-Cortolone glucuronide HMDB10320
20b-Cortolone glucuronide
20a,5a-Cortolone glucuronide
20b,5a-Cortolone glucuronide
Tetrahydrocortisol glucuronide
5a-Tetrahydrocortisol glucuronide
7.0 20a-Cortolone glucuronide HMDB10320
20b-Cortolone glucuronide
20a,5a-Cortolone glucuronide
20b,5a-Cortolone glucuronide
Tetrahydrocortisol glucuronide
5a-Tetrahydrocortisol glucuronide
7.2 M4 Olmesartan* HMDB14420
7.5 20a-Cortolone glucuronide HMDB10320
20b-Cortolone glucuronide
20a,5a-Cortolone glucuronide
20b,5a-Cortolone glucuronide
Tetrahydrocortisol glucuronide
5a-Tetrahydrocortisol glucuronide
7.9 20a-Cortolone glucuronide HMDB10320
20b-Cortolone glucuronide
20a,5a-Cortolone glucuronide
20b,5a-Cortolone glucuronide
Tetrahydrocortisol glucuronide
5a-Tetrahydrocortisol glucuronide
7.5 Tetrahydrocortisone glucuronide e
Tetrahydroaldosterone glucuronide HMDB10357
7.5 M5 e
7.9 11-Oxo-androsterone glucuronide HMDB10338
11-Oxo-etiocholanolone glucuronide
8.2 11b eHydroxyandrosterone glucuronide HMDB10351
11b-Hydroxyetiocholanolone glucuronide
6b-Hydroxyandrosterone glucuronide
6b-Hydroxyetiocholanolone glucuronide
8.3 M6 e e
8.8 11-Oxo-androsterone glucuronide HMDB10338
11-Oxo-etiocholanolone glucuronide
9.5 Testosterone glucuronide HMDB03193
10.5 Epitestosterone glucuronide e
Fig. 4. Endogenous biosynthetic and metabolic pathways for glucocorticoids, mineralocorticoids and sex hormones. Red boxes highlight steroids increased in the treatment group,
including possible isomeric forms. In boldface: isomeric forms predominant in urine. (For interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
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several isomeric forms of the isolated features not reported in this
repository. Notwithstanding, this point represented a limiting
aspect for data analysis and required further time-consuming
literature investigation. Anyway, we tried to obtain valuable infor-
mation in order to discriminate between detected peaks, consid-
ering previously reported isomers relative abundance in urine
[53,54]. On this basis we derived the final annotations reported in
Table 2 (and Table S-4) and Fig. 4.
The most remarkable metabolic signature characterizing the
treatment group resulted in an increase in the urinary excretion of
steroids in the anabolic androgenic cascade (TG and EG), together
with the final metabolic products of the glucocorticoid biosynthetic
pathway (Fig. 4). All these metabolites showed similar short-term
excretion profiles (Fig. 5), increasing in the treatment group and
decreasing in the predicted elimination phase. However, it has to be
underlined that in the context of the observational study involving
non-hospitalized men, it was not possible to withhold the subjects
for more than one day. Consequently, the groups of samples
investigated also show significant circadian steroidal fluctuations.
In particular, it is well established that cortisol (F) and cortisone
biosynthesis are subject to significant circadian regulation. A
related trend has been reported also for some of their metabolic
products in urine (tetrahydrocortisol G (THFG), 5a-tetrahy-
drocortisol G (5a-THFG), tetrahydrocortisone G (THEG), 5a-tetra-
hydrocortisone G (5a-THEG), and derived four isomers of cortolone
G) [55]. In particular, in healthy men blood F concentration reaches
a maximum around 9:00 a.m., while the related urinary metabo-
lites exhibit the peak about 2 h later. Of note, the treatment group
was collected approximately around noon, this meaning in
concomitance with the acrophase for the excretion of F metabolites
in urine. The short-term excretion profile (Fig. 5 A,C) supports this
interpretation. Interestingly, we also noticed a significant increase
in the excretion of 11-oxo-etiocholanolone G (11-oxoEtioG) and 11-
oxo-androsterone G (11-oxoAndroG), both final urinary metabo-
lites derived from F and cortisol (Figs. 4 and 5 A,C) even if for these
metabolites it has been previously reported no significant circadian
behavior in urine collected from healthy volunteers [55]. We also
detected an increase in metabolic features annotated in the HMDB
as 11b-hydroxyandrosterone G (11b-OHAndroG) and 11b-hydroxyetiocholanolone G (11b-OHEtioG). Of note, these metabo-
lites are also consistent with the non-hydrolyzable glucuronated
forms of 6b-OHAndro and 6b-OHEtio, recently reported as valuable
urinary markers providing extended detection window for oral T
administrations [49]. This observation also gives additional evi-
dence on the importance to perform additional studies to clarify
the utility of these novel markers also in the detection of topical T
intake, and supports their further evaluation for the inclusion in the
steroidal module of the ABP.
Although our findings are likely to be direct consequence of the
transdermal administration of T gel and are consistent with the
evidence reported in previous studies [30], we believe that for an
unambiguous interpretation of these data further studies have to
be specifically designed. In particular, larger cohorts are needed to
correct for the physiological circadian variability.
Beyond these modifications of the urinary steroidal profile, we
isolated three significantly increased metabolic features (M3, M4,
M5, see Table 2), with short term excretion profile consistent with
what expected after single administration of the steroidal formu-
lation (Fig. 5 D). Although no putative annotation was obtained, we
detected the related MS/MS fragments indicating the presence of
the glucuronic group (Table S-4), this supporting the possibility to
be associated to glucurono-conjugated metabolites of steroidal
compounds. Table S-4 reports the hypothesized molecular for-
mulas, computed considering the measured m/z values, isotopic
patterns and fragment ions relative abundances.
We also observed the putative increase of dietary components
(M1 andM2, caffeoyl methylquinic acid or ferulylquinic acid) and of
olmesartan (M4), an angiotensin II receptor antagonist indicated in
the treatment of hypertension (Table 2). Taking into account the
median age of the population of patients involved in the study
(about 62 years) and the presence of hypertension as comorbidity
state in the majority of these subjects, we infer the use of this drug
in the context of chronic therapeutic administrations, probably in
the morning, this explaining its presence in the group of samples
collected around 12:00 a.m.
Based on these evidences, the non-targeted workflow herein
developed provided us with a satisfactory portrait of the metabolic
signature of samples collected in the context of an observational
study characterized by high inter-individual metabolic variability.
Fig. 5. Short-term excretion profile for features increased in the treatment group. Normalized abundances in control (C), treatment (T) and elimination (E) samples for: A) 11-
oxoandrosterone glucuronide (11-oxoAndroG), 11-oxoetiocholanolone G (11-oxoEtioG), 11b-hydroxyandrosterone G (11b-OHAndroG) and 11b-hydroxyetiocholanolone G (11b-
OHEtioG), or 6b-hydroxyandrosterone G (6b-OHAndroG) and 6b-OH-Etiocholanolone G (6b-OHEtioG); B) testosterone G (TG), epitestosterone G (EG); C) tetrahydrocortisone G
(THEG), tetrahydrocortisolo G (THFG) (or 5a-tetrahydrocortisolo G, 5a-THFG), a-cortolone G, b-cortolone G, 5a-cortolone G, 20b,5a-cortolone G; D) Non identified and only pu-
tatively annotated metabolites (see Table 2 and Table S-3 for description). Error bars indicate ±1 standard error.
A. Palermo et al. / Analytica Chimica Acta 964 (2017) 112e122120Despite the complexity of the population under investigation and
the expected slight modifications of the steroidal profile as conse-
quence of single transdermal steroidal application, our approach
still succeeded in raising insights about most involved metabolic
pathways and in isolating previously not reported metabolic fea-
tures that correlate with samples clusters.
4. Conclusions
In this work we described a liquid-chromatography mass
spectrometry based metabolomics workflow optimized for the
non-targeted analysis of the urinary steroidal profile in the context
of the whole metabolic content of the sample. This method allowsthe detection of up to >3000 individual metabolic features among
witch >60% preliminary putatively annotated. For approximately
300 of them in each sample high reliability on measured ion
abundances was gauged, making the method germane also for
relative comparison of metabolites urinary levels. In addition, it
ensures sensitivity for steroids of doping and clinical relevance,
directly detected in the form of G and S conjugates, within physi-
ological urinary concentration ranges and after a naïve pretreat-
ment of approximately 100 mL of urine.
When applied for the analysis of a real cohort of urine samples,
the analytical and data analysis pipeline successfully delineates the
metabolic signature of each group, mainly due to circadian steroi-
dal fluctuations and to the increase in androgen metabolites
A. Palermo et al. / Analytica Chimica Acta 964 (2017) 112e122 121excretion. Noteworthy, it also permits the straightforward detec-
tion of other unexpected and previously unknown steroidal
metabolic features, contributing to the available reference back-
ground for future studies focused on the implementation of the
currently adopted urinary steroidal markers.
More in general, both forensic and clinical research can take
advantage of such holistic methodology as first line exploratory
strategy for the analysis of samples obtained in in vitrometabolism
studies and in vivo controlled administration trials. Indeed,
compared to classical targeted approaches (Fig. 1), non-targeted
analysis substantially extends the perspective moving the atten-
tion from isolated metabolic modifications towards a more defined
metabolic picture.
However, despite the great potentiality in biomarker discovery,
when dealing with the accurate validation of selected candidates
neither targeted nor non-targeted metabolomics can provide re-
sults not constrained by the availability of an adequate population
of samples in terms of i) number, ii) time of collection (e.g. in order
to circumvent circadian fluctuations) and iii) inclusion criteria for
individuals in the study cohort. These aspects prominently affect
the amount of undesired variability and reduce the isolable infor-
mative fraction from acquired data.
Furthermore, when coming to the non-targeted analysis of
steroidal metabolites including preliminary annotation against
currently available metabolite repositories, it has to be taken into
account that even if the number of metabolites included in these
databases is impressive, it does not yet cover the entire available
knowledge about human metabolism. In particular, in the case of
the urinary steroidal profile we found several isomeric forms and G
and S conjugates thereof, not reported in databases but broadly
described in literature. This represents a time consuming bottle-
neck in metabolomics and suggests that a critical interpretation of
obtained data on the basis of currently available knowledge re-
mains an important step whenever high level of accuracy and so-
lidity is required.
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Summary of abbreviations
T Testosterone
E Epitestosterone
Andro Androsterone
Etio Etiocholanolone
5aAdiol 5a-androstane-3a,17b-diol
5bAdiol 5b-androstane-3a,17b-diol
DHEA Dehydroisoandrosterone
F Cortisol
THF Tetrahydrocortisol
THE Tetrahydrocortisone
aTHF 5a-tetrahydrocortisol
aTHE 5a-tetrahydrocortisone
11-oxoEtio 11-oxo-etiocholanolone
11-oxoAndro 11-oxo-androsterone
11b-OHEtio 11b-hydroxyetiocholanolone11b-OHAndro 11b-hydroxyandrosterone
6b-OHEtio 6b-hydroxyetiocholanolone
6b-OHAndro 6b-hydroxyandrosterone
G Glucuronide
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